Reference
- Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79(1): 1–17
- Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular- weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326(15): 975–82
- Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-andthrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86(2): 385–91
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20): 1330–5
- Weitz J, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993; 122(4): 364–73
- Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64(4): 506–10
- Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339(8791): 441–5
- Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72(2): 186–90
- Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995; 155(6): 601–7
- Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334(11): 677–81
- Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334(ll): 682–7
- Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus Standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340(8812): 152–6
- Kakkar W. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemost 1995; 74(1): 364–8
- O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxa- parin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994; 150(7): 1083–90
- Melissa E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68(6): 652–6
- Rasmussen C, Wadt J, Jacobsen B. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int J Gynaecol Obstet 1994; 47(2): 121–5
- de Valk HW, Banga JD, Wester JW, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial. Ann Intern Med 1995; 123(1): 1–9
- Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70 (4): 554–61 [Erratum, Thromb Haemost 1993: 70(6): 1072]
- Weitz JI, Califf RM, Ginsberg JS, et al. New antithrombotics. Chest 1995; 108(4 Suppl): 471–85S
- Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333(12): 757–63
- Bittl JA, Strony J, Blinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333(12): 764–9
- Soutar RL, Ginsberg JS. Anticoagulant therapy with ancrod. Crit Rev Oncol Hematol 1993; 15(l): 23–33